A clinical-stage neuroscience company developing breakthrough therapies for psychiatric and neurological disorders, with a focus on next-generation neuropsychiatric treatments.
Formed as a spinout following the 2025 acquisition by AbbVie, the company inherits clinical and preclinical programs and continues development of neuroplastogen-related assets and collaborations with biopharma partners.
Leadership & Board
Current Number of Employees37
Current LinkedIn Followers11,535
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$60M
Total Amount Raised$60M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$60M
Latest Funding Amount$60M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Gilgamesh Pharma had 37 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
37Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Gilgamesh Pharma had 11,535 followers as of September 28, 2026. The number of followers increased by 23 (0.20%) week-over-week.
11,535Latest Followers Count
23(0.20%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Mar 24, 2026
Series A
$60.00M
―
Similar Companies
A snapshot of private companies similar to Gilgamesh Pharma, helping you discover and navigate related company profiles.